case_images: PMC6247720_01
case_images: Case 1: biweekly romiplostim.
case_images: CRIHEM2018-6037494.001.jpg
case_images: PMC6247720_01_CRIHEM2018-6037494.001.jpg
case_images: fig1
case_images: Due to platelet counts remaining in the 200-600 x 109/L range, she was switched to biweekly dosing of romiplostim 250 microg and was able to maintain stable platelet counts for 11 consecutive weeks (Figure 1).
case_images: PMC6247720_02
case_images: Case 2: biweekly romiplostim.
case_images: CRIHEM2018-6037494.002.jpg
case_images: PMC6247720_02_CRIHEM2018-6037494.002.jpg
case_images: fig2
case_images: The patient was able to maintain stable platelet counts for 131 consecutive weeks; however, due to a lapse in private medication coverage, the patient discontinued romiplostim altogether (Figure 2).
case_images: PMC6247720_03
case_images: Case 3: biweekly romiplostim.
case_images: CRIHEM2018-6037494.003.jpg
case_images: PMC6247720_03_CRIHEM2018-6037494.003.jpg
case_images: fig3
case_images: She maintained stable platelet counts on weekly romiplostim dosing for 94 weeks before being switched to biweekly romiplostim 75 microg therapy and was able to maintain stable platelet counts for 20 weeks (Figure 3).
case_images: Case 3: triweekly romiplostim.
case_images: CRIHEM2018-6037494.004.jpg
case_images: PMC6247720_03_CRIHEM2018-6037494.004.jpg
case_images: fig4
case_images: On q3weekly dosing, she was still able to maintain high platelet counts for 12 weeks (Figure 4), and thus, romiplostim therapy was discontinued altogether while monitoring the patient closely.